Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 43Active not recruiting 11Unknown 10Terminated 7Withdrawn 5Recruiting 5Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 9Rectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 6Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Glioblastoma 4Esophageal Neoplasms 4Brain Neoplasms 4Neoplasms 3Nasopharyngeal Carcinoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Adenocarcinoma 2Spinal Cord Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Rhabdomyosarcoma 1Rectal Cancer Patients 1Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pelvic Neoplasms 1

Interventions

anlotinib 3Injections 3Doxorubicin 3toripalimab 1spartalizumab 1penpulimab 1pemigatinib 1pazopanib 1montelukast 1liposomal doxorubicin 1eribulin 1chlorhexidine gluconate 1camrelizumab 1bexmarilimab 1apatinib 1X-Rays 1Trabectedin 1Temozolomide 1Tablets 1Surgical Procedures, Operative 1Sodium Chloride 1Radiotherapy 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Neoadjuvant Therapy 1Negative-Pressure Wound Therapy 1KP 1339 1Ipilimumab 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Sarcoma × Radiotherapy × Clear all
NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

Fudan University

Phase 2 Not yet recruiting
46 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡